| Literature DB >> 31728104 |
Andrea Estébanez1, Nuria Estébanez2, Jose M Martín1, Encarna Montesinos1.
Abstract
Alopecia areata (AA) is a common disease characterized by nonscarring hair loss. There are no satisfactory therapies for extensive cases. Systemic immune suppressants are usually used despite their nonspecific actions and often associated side effects. Apremilast is an oral, small-molecule, inhibitor of phosphodiesterase 4 approved for the treatment of psoriasis and psoriatic arthritis. Its use in AA has shown variable results. Whereas a recent reduced clinical trial concluded a lack of efficacity, several case reports demonstrate a significant improvement. We report four cases of extensive AA successfully treated with apremilast. Copyright:Entities:
Keywords: Alopecia areata; alopecia; apremilast
Year: 2019 PMID: 31728104 PMCID: PMC6830030 DOI: 10.4103/ijt.ijt_59_19
Source DB: PubMed Journal: Int J Trichology ISSN: 0974-7753